Kojiro Shimozuma

4.1k total citations
148 papers, 3.1k citations indexed

About

Kojiro Shimozuma is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kojiro Shimozuma has authored 148 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 38 papers in Economics and Econometrics and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kojiro Shimozuma's work include Cancer Treatment and Pharmacology (36 papers), Health Systems, Economic Evaluations, Quality of Life (34 papers) and Breast Cancer Treatment Studies (25 papers). Kojiro Shimozuma is often cited by papers focused on Cancer Treatment and Pharmacology (36 papers), Health Systems, Economic Evaluations, Quality of Life (34 papers) and Breast Cancer Treatment Studies (25 papers). Kojiro Shimozuma collaborates with scholars based in Japan, United States and Switzerland. Kojiro Shimozuma's co-authors include Takeru Shiroiwa, Takashi Fukuda, Shinya Saito, Katsumasa Kuroi, Shozo Ohsumi, Yasuo Ohashi, Shunya Ikeda, Shinichi Noto, Ataru Igarashi and Hirohisa Imai and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Kojiro Shimozuma

140 papers receiving 3.0k citations

Peers

Countries citing papers authored by Kojiro Shimozuma

Since Specialization

Citations

This map shows the geographic impact of Kojiro Shimozuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kojiro Shimozuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kojiro Shimozuma more than expected).

Fields of papers citing papers by Kojiro Shimozuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kojiro Shimozuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kojiro Shimozuma. The network helps show where Kojiro Shimozuma may publish in the future.

Co-authorship network of co-authors of Kojiro Shimozuma

This figure shows the co-authorship network connecting the top 25 collaborators of Kojiro Shimozuma. A scholar is included among the top collaborators of Kojiro Shimozuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kojiro Shimozuma. Kojiro Shimozuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EE289 Cost-Effectiveness Analysis of Blinatumomab for Advanced Acute Lymphoblastic Leukemia in Japan 2024 ·Value in Health ·(unknown), Kensuke Moriwaki, Kenichi Morimoto, Kojiro Shimozuma	0
2	HTA42 Vignette-Based Estimation of Utilities in Patients with Metastatic Breast Cancer in Japan 2024 ·Value in Health ·Motoko Yamaguchi, Kensuke Moriwaki, Kojiro Shimozuma	0
3	Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial 2024 ·EClinicalMedicine ·Masato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, Naruto Taira, (unknown), Kojiro Shimozuma, Ohtani Shoichiro, Tetsuhiro Yoshinami, Junichiro Watanabe, Masahiro Kashiwaba, (unknown), Masahiro Kitada, Koichi Sakaguchi, Yuko Tanabe, Tomohiko Aihara, Hirofumi Mukai	3
4	How to select and understand guidelines for patient-reported outcomes: a scoping review of existing guidance 2024 ·BMC Health Services Research ·(unknown), Eri Hoshino, Mariko Naito, Yoshimi Suzukamo, (unknown), (unknown), Takuhiro Yamaguchi, Takashi Kawaguchi, Tempei Miyaji, Takako Eguchi Nakajima, Kojiro Shimozuma	2
5	Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan 2022 ·Clinical Drug Investigation ·Xiuting Mo, Kensuke Moriwaki, (unknown), Kojiro Shimozuma	4
6	Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan 2021 ·PharmacoEconomics - Open ·Kensuke Moriwaki, (unknown), (unknown), (unknown), Kojiro Shimozuma	6
7	Response Shift–Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling 2020 ·Value in Health ·Tatsunori Murata, Yoshimi Suzukamo, Takeru Shiroiwa, Naruto Taira, Kojiro Shimozuma, Yasuo Ohashi, (unknown)	6
8	Psychometric properties of the Japanese version of the EQ-5D-Y by self-report and proxy-report: reliability and construct validity 2019 ·Quality of Life Research ·Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma	32
9	Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan 2016 ·Value in Health ·Takeru Shiroiwa, Shunya Ikeda, Shinichi Noto, Ataru Igarashi, Takashi Fukuda, Shinya Saito, Kojiro Shimozuma	212
10	Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making 2016 ·Applied Health Economics and Health Policy ·Takeru Shiroiwa, Shinya Saito, Kojiro Shimozuma, (unknown), Shinichi Noto, Takashi Fukuda	9
11	Developing a Japanese version of the EQ-5D-5L value set 2015 ·Shunya Ikeda, Takeru Shiroiwa, Ataru Igarashi, Shinichi Noto, Takashi Fukuda, Shinya Saito, Kojiro Shimozuma	127
12	Guideline for economic evaluation of healthcare technologies in Japan 2013 ·Takashi Fukuda, Takeru Shiroiwa, Shunya Ikeda, (unknown), (unknown), H Ishida, Shinichi Noto, (unknown), (unknown), Kojiro Shimozuma, Tomoyuki Takura, Haruhisa Fukuda, Kensuke Moriwaki, (unknown), (unknown)	46
13	QALY and Productivity Loss: Empirical Evidence for “Double Counting” 2013 ·Value in Health ·Takeru Shiroiwa, Takashi Fukuda, Shunya Ikeda, Kojiro Shimozuma	35
14	6. The Ethics of the Allocation of Health Care Resources and QALY 2012 ·Shinya Saito, (unknown), Takeru Shiroiwa, Kojiro Shimozuma, Shinichi Noto, (unknown)	0
15	2. How to Handle with ^\|^quot;Unrelated Cost^\|^quot; in Economic Evaluation? 2012 ·Ataru Igarashi, (unknown), Takeru Shiroiwa, Makoto Kobayashi, Manabu Akazawa, Shunya Ikeda, Takashi Fukuda, Kojiro Shimozuma	1
16	1. Issues on Estimating Costs in Economic Evaluation 2012 ·Hiroyuki Sakamaki, H Ishida, Takashi Fukuda, Takeru Shiroiwa, Kojiro Shimozuma	1
17	Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial 2011 ·British Journal of Cancer ·Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma	54
18	Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial 2011 ·Value in Health ·Takeru Shiroiwa, (unknown), Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi	15
19	Comparison of EQ-5D Scores among Anthracycline-Containing Regimens followed by Taxane and Taxane-Only Regimens for Node-Positive Breast Cancer Patients after Surgery: The N-SAS BC 02 Trial 2011 ·Value in Health ·Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Masaru Kuranami, Kimito Suemasu, Yasuo Ohashi, Toru Watanabe	10
20	Aged Garlic Extract Prevents a Decline of NK Cell Number and Activity in Patients with Advanced Cancer 2006 ·Journal of Nutrition ·Hideki Ishikawa, (unknown), Toru Otani, Takaichiro Suzuki, Kojiro Shimozuma, Hoyoku Nishino, Sanae Fukuda, Kanehisa Morimoto	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact